Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sandoz Will Consider Local Partnerships In China

Executive Summary

As it builds a portfolio in the Chinese market, which is increasingly focused on high-quality products, Sandoz is considering teaming up with local players for certain drugs.

You may also be interested in...

Sandoz’ Unique Chinese Approval Paves The Way For Tender Access

Sandoz says a first-of-its-kind Chinese approval for generic rosuvastatin will open the door for the firm to participate in local tenders.

Sandoz Forms Insulin Biosimilars Deal With Gan & Lee

In line with its strategy to expand its biosimilars business, Sandoz has entered into an agreement with China’s Gan & Lee to market and supply three insulin biosimilars in the EU, US, and other key territories.

Sandoz Sees Market Opening Up In China

As China’s government raises quality standards for generics, Sandoz views the local market as promising, according to the Novartis division’s head, Richard Francis.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts